Since the discovery of the notch pathway 25 years ago, several studies have found a link between different Notch receptors and specific forms of breast cancer, including triple-negative.
Although TKI therapy is highly effective, it is expensive, and may cost $146,000 per year on average if a patient is uninsured. High expenses make it difficult even for insured patients to meet their copayments and coinsurance costs.
The gene expression-based prognostic model, RHL30, has the potential to provide insights for the selection of treatment strategies catered to the individual patient.
As patients become older, additional factors must be considered in planning their treatment.
A new study finds some hopeful signs of progress in understanding blast phase CML, which is typically associated with poor outcomes.
With researchers around the world directing their attention at the role and potential of miRNAs in RCC diagnosis and therapy, our understanding of the molecules is accelerating.
With the average uninsured cost of TKI treatment close to or above $146,000 per year per patient with CML in the United States, reducing or ending treatment would yield billions in savings.
Chronic myeloid leukemia patient outcome study finds high correlation between insurance status at diagnosis and overall patient survival.